Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

February 14, 2013

Primary Completion Date

May 1, 2014

Study Completion Date

May 1, 2014

Conditions
Hypertension
Interventions
DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily

Trial Locations (82)

1820

Steenokkerzeel

2100

Deurne

3545

Ham

9230

Wetteren

9310

Moorsel

12627

Berlin

21075

Elkridge

28150

Shelby

29464

Mt. Pleasant

29615

Greenville

30338

Atlanta

32216

Jacksonville

33009

Hallandale

33083

Hollywood

33458

Jupiter

33606

Tampa

36535

Foley

37203

Nashville

37825

New Tazewell

39104

Magdeburg

40504

Lexington

43213

Columbus

44787

Bochum

45224

Cincinnati

45245

Cincinnati

45246

Cincinnati

46383

Valparaiso

53142

Kenosha

57702

Rapid City

60313

Frankfurt am Main

63141

St Louis

67114

Newton

67205

Wichita

70119

New Orleans

75010

Carrollton

75230

Dallas

77701

Beaumont

77802

Bryan

78229

San Antonio

84109

Salt Lake City

84121

Salt Lake City

90057

Los Angeles

91978

Spring Valley

95608

Carmichael

06460

Milford

33114-4192

Coral Gables

04240

Auburn

02301

Brockton

V5G 1T4

Burnaby

V3A 4H9

Langley

V5Z 1K3

Vancouver

L6T 0G1

Brampton

L7M 4Y1

Burlington

M8V 3X8

Etobicoke

N5W 6A2

London

L3Y 5G8

Newmarket

N7T 4X3

Sarnia

L0M 1S0

Stayner

M4S 1Y2

Toronto

M9V 4B4

Toronto

N4S 4G3

Woodstock

H9R 3J1

Pointe-Claire

G1W 1S2

Ste-Foy

02826

Görlitz

04103

Leipzig

Unknown

Dresden

81-384

Gdynia

40-040

Katowice

01-192

Warsaw

50-088

Wroclaw

RG2 0TG

Reading

S40 4AA

Chesterfield

FY3 7EN

Blackpool

BA3 2UH

Bath

IP30 9QU

Bury Saint Edmonds

CV6 4DD

Coventry

B15 2SQ

Birmingham

CF14 5GJ

Cardiff

PR7 7NA

Chorley

G20 OSP

Glasgow

L22 0LG

Liverpool

M15 6SX

Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01788358 - Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension | Biotech Hunter | Biotech Hunter